Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
July 31, 2025
Earnings Call Speaker Segments
Morgan Sanford
executiveThank you, operator. Everyone, good morning. Morgan Sanford here, and I serve as Vice President of Investor Relations at Agios. We appreciate you being with us for this discussion of Agios Pharmaceuticals' Second Quarter 2025 Financial Results and Business Highlights. To view the slides accompanying today's call, please visit the Investors portion of our site, agios.com. Kindly advance to the following slide. We will be sharing some forward-looking statements during this session. Those statements involve risks, and real outcomes may end up differing materially from what any of them express or imply. This is due to a range of risks, uncertainties and other factors, among them the ones described in our latest SEC filings as well as any additional documents we might file with the SEC later. Please go to the next slide. Joining me on today's call from Agios are Brian Goff, our Chief Executive Officer; Cecilia Jones, our Chief Financial Officer; Tsveta Milanova, our Chief Commercial Officer; and Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development. Once the prepared remarks are finished, the line will be opened so you can ask questions. So with that, let's move to the next slide, and it's my pleasure to hand things over to Brian.
Brian Goff
executiveAppreciate that, Morgan. Morning to all of you, and thanks for being with us on this call today. Let's go to the following slide. For Agios, 2025 is looking like a breakthrough year, and our belief is that we have an obvious route to produce durable growth and to unlock value for shareholders over the long term. To start, we hold a multibillion-dollar opportunity with reduced risk in PYRUKYND, our first-in-class PK activator. Second, as we get closer to a number of near-term catalysts with high value, momentum keeps building. Assuming the FDA gives the green light, our hope is to make thalassemia the second approved indication for PYRUKYND in the U.S., and from our September 7 PDUFA goal date we are now fewer than 40 days away. Before this year wraps up, we expect to report results from the RISE UP Phase III trial of PYRUKYND in sickle cell disease, and in the early part of next year, we anticipate Phase IIb data for tebapivat, our more potent PK activator, in patients with anemia due to lower-risk myelodysplastic syndromes. And third, our capitalization is strong enough to develop and launch PYRUKYND in thalassemia and sickle cell disease, to keep pushing forward our current development programs, and to seek chances to broaden our pipeline via internal work and business development efforts. Kindly advance to the next slide. During the second quarter, net revenue came in at $12.5 million, which speaks to the compelling value proposition of PYRUKYND; we signed an agreement with Avanzanite Bioscience for commercializing and distributing PYRUKYND across Europe. This deal is capital-efficient, letting us concentrate our investment on U.S. commercial launches; we closed the second quarter with roughly $1.3 billion in cash, cash equivalents and marketable securities, and our intention is to stay disciplined in how we invest behind the commercial build-out of PYRUKYND and the advancement of our pipeline. In Q2, we dosed the first patient in the Phase II trial of tebapivat for sickle cell disease and got IND clearance for AG-236, our siRNA aimed at TEMPRSS6 and intended to treat polycythemia vera. Our growth story has reached a significant turning point. In the near term, we may be able to transform how thalassemia and sickle cell disease are treated with PYRUKYND; and further out, we have a chance to bring additional medicines to rare disease patients who are waiting and have urgent need of innovative treatment options. Please go to the next slide, and I'll hand the call over to Cecilia for further commentary on our second quarter performance and the future trajectory for PYRUKYND.
Cecilia Jones
executiveThanks, Brian. Could we go to the next slide? The financial results for the second quarter of 2025 are included in the press release that went out earlier this morning, and you can find further information in our 10-Q, which we'll be filing later today. So let me take a moment now to give some context and walk through a few key points. Net PYRUKYND revenue in the second quarter came to $12.5 million, which is up 45% from $8.6 million in the second quarter of 2024, and up 44% from $8.7 million in the first quarter of 2025. The sequential growth in net revenue reflects our continued commercial execution in PKD, along with an additional week of ordering during the second quarter and more units being processed directly by the specialty pharmacy. As we move through the second half of the year, we anticipate that net revenues will continue to show quarter-on-quarter variability because of ordering patterns. If thalassemia is approved in the U.S., we expect PKD demand to soften as our sales force shifts its promotional focus toward thalassemia. We continue to expect that the fourth quarter will reflect only partial thalassemia demand, given the timing of a PDUFA goal date and how long it should take to convert patient enrollment forms into treatment initiations. Putting that all together, on a full year basis across all indications, we expect net revenues for 2025 to show modest growth relative to 2024. Cost of sales for the quarter was $1.7 million. R&D expenses came in at $91.9 million, which is an increase of $14.5 million versus the second quarter of 2024; that rise was mainly attributable to a $10 million milestone payment made to our partner Alnylam tied to the development of AG-236. SG&A expenses totaled $45.9 million in the second quarter, up $10.4 million from the prior year, reflecting continued investment ahead of the potential commercial launch of PYRUKYND for treating thalassemia. We finished the second quarter with roughly $1.3 billion in cash, cash equivalents and marketable securities. Next slide, please. Our strong balance sheet underpins our focused capital allocation strategy, which lets us invest in our next wave of growth and pipeline delivery. First, we've carried out a capital-efficient commercial build-out, putting priority on investment in potential U.S. launches, where the commercial opportunity is largest. Last year, we announced our partnership with NewBridge Pharmaceuticals to commercialize PYRUKYND in the GCC. And last month, we signed an agreement with Avanzanite Bioscience to commercialize and distribute PYRUKYND in Europe. Both deals are structured as revenue-sharing arrangements that benefit Agios over the long term. We'll record our share of ex-U.S. sales as net revenues. Second, we're making strategic investments in our pipeline to move our early and mid-stage clinical programs forward. Third, we'll look opportunistically for ways to expand our pipeline, whether through internal efforts or assets sourced externally. To wrap up, I'm confident our balance sheet will allow us to keep executing from a position of strength. If everyone could move on to the following slide, I'll now hand things over to Tsveta, who will walk us through the commercial highlights from this quarter.
Tsveta Milanova
executiveThanks, Cecilia. Could we advance to the following slide? The net revenue increase we saw in Q2 is a result of solid work from our commercial organization. Even so, we still expect fluctuation from one quarter to the next, driven by the ordering and inventory patterns that are common with rare disease therapies. By the end of the second quarter, prescription enrollment forms had been completed for 248 patients, which is a 6% gain over Q1 of 2025. Active PYRUKYND treatment now includes 142 patients, representing sequential growth of 4%. Kindly go to the subsequent slide; with fewer than 40 days remaining until our PDUFA goal date, our commercial organization stands fully ready to launch in thalassemia, assuming FDA approval. We have confidence in PYRUKYND's compelling clinical profile, which has been demonstrated in 2 Phase III trials: ENERGIZE, involving non-transfusion-dependent patients, and ENERGIZE-T, involving transfusion-dependent patients. As this slide illustrates, the data produced throughout this extensive clinical program means that, should approval come, we are positioned to achieve a series of firsts in treating thalassemia within the U.S., each of which carries deep significance for those living with thalassemia. Could we go to the next slide? Our confidence in executing the U.S. launch of PYRUKYND for thalassemia, assuming FDA approval, rests on several factors. To begin with, thalassemia is effectively diagnosed because newborn patient screening is widespread across the U.S. Furthermore, because claims data and ICD-10 codes are available, these individuals have a well-documented history of interacting with health care services. Secondly, disease burden is substantial, which means symptomatic patients receive active management, and the related expense of care is considerable. Even so, therapeutic choices remain few, particularly for those with non-transfusion-dependent disease, and the majority of patients continue to depend on supportive therapy. Thirdly, this community shows significant involvement from key thought leaders along with strong patient advocacy representation. In fact, during this month we took part in the inaugural Thalassemia International Federation Pan-American Conference, where we held substantive discussions with patients and physicians that deepen our grasp of what they need. Finally, thorough preparation underpins our capacity to execute a successful launch. Our disease state education is designed to reflect the varied multicultural dimensions of thalassemia, and we have drawn on our relationships with thought leaders to offer further disease education to community-based physicians. During the prior year, we expanded our sales force by twofold, reaching roughly 40 employees, and have centered our launch planning on recognized treatment centers. Early payer discussions have been favorable, bolstered by the persuasive benefit risk profile of PYRUKYND. Kindly proceed to the next slide. We have concentrated our capital investments within the U.S., which stands as the biggest commercial opportunity worldwide, with 6,000 diagnosed adult thalassemia patients. Our initial launch targets the 4,000 patients who are actively managed because of their symptomology. This patient group encompasses both transfusion and non-transfusion-dependent patients who face complications and/or are dealing with debilitating fatigue. Could we have the next slide? Our arrangement with Avanzanite Bioscience and NewBridge Pharmaceuticals enables us to offer sustainable, tailored access to PYRUKYND beyond the U.S. We expect the first possible regulatory approval in the GCC within the next few months, and I'll provide more specifics on how the commercial launch will unfold in that region in just a moment. For Europe, we're looking at a potential regulatory decision in early 2025. There, we'll collaborate with our partner, Avanzanite, on a targeted launch approach done country by country, in line with the prevalence of thalassemia disease. Let's go to the next slide. I'd like to spend a few minutes drilling into the opportunity in the GCC. Roughly 70,000 adult and pediatric thalassemia patients are estimated to live in the GCC, irrespective of genotype and phenotype. And most of that estimated prevalence is concentrated in Saudi Arabia. That said, because national registry data is lacking, we've been collaborating with our partner, NewBridge, to sharpen our launch strategy. Because access is patchy throughout the region, our focus is on all patients receiving active treatment at a hospital, which means the launch population we're targeting accounts for a more modest portion of the estimated 70,000 prevalence. A key point is that we believe we can broaden access through national procurement deals, and getting those in place typically takes about two years after approval; while that process plays out, access gets provided one patient at a time. After procurement deals are in hand, we anticipate widening access further through institutional-level agreements. We're delighted to work alongside NewBridge, which brings deep experience in commercializing therapies across the GCC, as we look to potentially reshape how thalassemia is treated in Saudi Arabia and the United Arab Emirates. Let's turn to the next slide. With that said, I'll now pass things along to Sarah, who will walk us through the main R&D developments from this quarter.
Sarah Gheuens
executiveThanks, Tsveta. Let's bring up the following slide. PYRUKYND, which is our first-in-class PK activator, has produced consistent and meaningful clinical results spanning several hemolytic anemias, which strengthens the case for its distinctive mechanism of action as an allosteric activator of PKR as well as PKM2, and for how broadly that unique mechanism can be applied. In pyruvate kinase deficiency, the first indication we won approval for, PYRUKYND treatment generated statistically significant gains on numerous endpoints, underscoring better hemoglobin levels, less hemolysis, and improved patient-reported outcomes. Late last year, we filed a supplemental NDA for PYRUKYND covering treatment of alpha or beta thalassemia irrespective of transfusion burden. Through our Phase III ENERGIZE and ENERGIZE-T studies, we demonstrated statistically significant gains on anemia measures, such as hemoglobin levels, transfusion reduction, and less fatigue. We keep collaborating with global health authorities regarding our regulatory filings and are working toward our PDUFA goal date in the U.S. In sickle cell disease, we reported compelling Phase II data during 2023 from the operationally seamless RISE UP Phase II/III trial, and we remain on track to deliver top line results from the Phase III trial by the end of the year. Kindly advance to the following slide. Last month, during the European Hematology Association Congress, we had 14 abstracts combined, which generated multiple oral presentations, posters, and publications, mostly centered on PYRUKYND and tebapivat. These data bolster the robust collection of efficacy and safety data, reinforcing the promise of PK activation and the therapeutic potential of mitapivat and tebapivat spanning a range of devastating rare diseases, among them pyruvate kinase deficiency, thalassemia, sickle cell disease, and myelodysplastic syndromes. Kindly advance to the following slide. Our RISE UP Phase II data strengthen our confidence in the potential to deliver a statistically significant improvement in hemoglobin response and reduction in analyzed rate of sickle cell pain crisis, which serve as the dual primary endpoints for our Phase III trial. Because how often sickle cell pain crisis occurs and how severe it is can vary, we maintained consistency between our Phase II and Phase III trials by applying the same inclusion and exclusion criteria, the same definition of pain crisis, the same adjudication committee and methodology, and by including sites from the Phase II within the Phase III trial. We aim to deliver data that can speak to the positive impact PYRUKYND may show on the totality of the disease, for instance, hemolytic anemia and vaso-occlusion. In addition, since fatigue matters to patients, we will examine the improvement in the thrombocytic scale as one of our key secondary endpoints. We believe our robust trial design offers multiple pathways to deliver clinically meaningful data and a differentiated profile with PYRUKYND. Following slide, please. We keep advancing our pipeline and are now investigating our potential best-in-class PK activator franchise, made up of PYRUKYND and tebapivat, spanning 4 rare diseases. Additionally, we're thrilled to move forward with the Phase I multiple ascending dose study of AG-181, which is meant to treat phenylketonuria, plus the Phase I single ascending dose study of AG-236, aimed at treating polycythemia vera. As Brian noted, during Q2 we hit the 2 corporate goals we had set for the middle of the year, involving tebapivat and AG-236. These results strengthen our steady, impressive history of meeting our pipeline milestones. I'm eager to share further pipeline news with you as we aim to build a strong portfolio of therapies that can change how rare diseases are treated. So please advance to the next slide, and I'll give the call back to Brian for his closing comments.
Brian Goff
executiveThanks, Sarah. Let's pull up the following slide. During Q2, we delivered solid momentum on the objectives we set for 2025. We hit key milestones that move tebapivat and AG-236 forward — 2 programs that could extend our footprint into additional rare disease indications. Our view is that 2025 stands to be a breakthrough year for Agios, as we push ahead toward a possible U.S. launch of PYRUKYND in thalassemia, the Phase III RISE UP readout in sickle cell disease, and ongoing progress across our mid and early-stage pipeline. On to the next slide, please. To wrap up, Agios holds what it takes to bring innovative medicines to rare disease patients who need them, fueling durable growth and creating long-term value for shareholders. At our foundation, we draw energy from the ties we have with the rare disease communities we support, which lets us produce clinical benefits that matter to patients, paired with a commercial approach tailored to reach patients wherever they are. Crucially, we are progressing toward a diversified rare disease portfolio. We're moving quickly on a best-in-class PK activator franchise, with potential across 4 indications, and we anticipate sharing future updates on our early-stage pipeline, which gives us a chance to speed up growth beyond hematology. Prior to turning to Q&A, I want to express my gratitude to the investigators and patients, whose involvement, collaboration and confidence have been so valuable to our development efforts. And naturally, the Agios team, who inspire me daily; we're eager for what lies ahead as we work to reshape the future of rare diseases. With that said, I'd like to begin the question-and-answer portion. Operator, please open the line.
Eric Schmidt
analystThis is Imogen calling in for Eric. Previously, I believe you stated that investors would be informed about any shift in mitapivat's safety profile, covering instances of liver toxicity in patients beyond thalassemia. Do you have anything fresh to share on that front?
Brian Goff
executiveThis is Brian. I appreciate the question very much. For the first item, regarding any developments concerning the safety profile, I'll ask Sarah to weigh in.
Sarah Gheuens
executiveSo no updates to the safety profile; that's it really.
Analyst
analystAll right, that's helpful. Then I have a brief follow-up question about when the GCC might grant its approval — could you offer any additional detail there? Should we be looking for that possibly right after the U.S. gives its green light?
Brian Goff
executiveSure. If I think back to what we told everyone back in December of last year, one thing that makes me genuinely proud is that our team managed to file — Agio had never done this before — in 4 separate regions all at once. The only thing we're able to say right now is that conversations are ongoing in each of those 4 regions, and we're eager for the chance to bring everyone up to date regarding where those reviews stand. And I'd add that Tsveta, along with her group, is absolutely prepared when it comes to commercialization.
Marc Frahm
analystMarc, thanks. So, maybe since the thal review is still going on, can you say whether you might already be in labeling talks? And clearly, the safety info will need at least some updating, just to reflect that thalassemia is now, hopefully, going to turn into an approved indication. So what are the latest thoughts on how you expect that portion of the label to look? And then I'll likely have a follow-up.
Brian Goff
executiveBrian: Yes. Thanks, Marc. So, Sarah can begin.
Sarah Gheuens
executiveOkay, thank you, Marc. So perhaps only to summarize. Yet, as you're aware, as Brian just pointed out, we have filed in 4 separate areas for the thalassemia indication, which rests on our 2 tightly controlled studies that hit the primary and key secondary endpoints in each. That covers the benefit side. You brought up the risk side: naturally, there is the hepatocellular injury, which is already visible in the PKD label that came from the thalassemia findings. Therefore, we at a minimum expect an update there in the PKD label, so that the indication statement is reflected and the dose is switched to thalassemia and 100 milligrams BID. However, the process and the review are, naturally, still underway, and the FDA gives you only a completion date for the full review. Thus, the final label is what we'll learn on the PDUFA date.
Marc Frahm
analystAll right, that helps. Now, this question is really directed at Tsveta and Cecilia. SG&A expense has clearly been creeping upward as you expand and get ready for the thalassemia launch. Is it fair to think of that figure as now fully in place, meaning it represents the ongoing run rate? Or should we anticipate additional significant increases down the road once the launch really gets under way?
Brian Goff
executiveSure. Perhaps Cecilia can begin with the financial side, and then Tsveta, who never passes up a chance, can explain how thoroughly her team has prepared for the launches that lie ahead.
Cecilia Jones
executiveAppreciate that, Mike. Yeah, looking at it from the financial angle, we are anticipating somewhat greater expansion when it comes to SG&A for thalassemia. That's correct — the majority of the infrastructure got put in place with the sales teams and the customer-facing teams beginning last year once the trials read out, though there are certain launch-related expenses we have that clearly would only occur if approval comes through. So potentially we see additional ones arriving after that point.
Tsveta Milanova
executiveYes, without a doubt. And I can tell you the team is prepared for a possible thalassemia launch. Like Cecilia said, we rolled out the field-facing organization toward the end of last year, and that covers the 40 — roughly 40 individuals in sales, plus a cross-functional group serving different customers. We're thrilled about the chance to offer PYRUKYND for thalassemia, naturally subject to FDA approval in the U.S., and we look forward to sharing updates whenever we can.
Salveen Richter
analystWith the PDUFA date for thal coming up and attention turning toward the launch, could you give us a sense of which patient group you plan to reach first — the initial population you'll be going after?
Brian Goff
executiveSure. Much appreciated, Salveen; once more, I'll hand that question to Tsveta.
Tsveta Milanova
executiveSure. Looking at it commercially, thalassemia stands out as a genuinely appealing indication for a potential next launch on our part. Why is that? Because in the U.S., patients who have thalassemia are in fact diagnosed and already well recognized by the health care system. We have strong data derived from the ICD-10 code here in the U.S., and we've managed to validate that through our conversations with health care professionals. That provided us with substantial clarity — not just regarding where those patients receive care today, but also regarding which patients we ought to prioritize and focus on when we launch. If you consider which patients make the most suitable initial launch target, it comes to roughly 4,000 patients, drawn from the 6,000 adults in the U.S. who carry a diagnosis. Our method of prioritizing these patients rests on their symptomology, on the fact that they're engaged with the health care system, and on their potential need for further management and treatment. Within this patient group, you find both transfusion-dependent patients, who may be seeking to lower their transfusion burden, and non-transfusion-dependent patients who are symptomatic — dealing with fatigue and other complications of the disease — and in both cases the patient and the physician may be searching for additional management and treatment. As I mentioned, the team is extremely well prepared for the launch, and we have the chance to engage with these accounts ahead of the launch. One thing that's very important for us: we must remember and recognize that thalassemia is a disease carrying high unmet need. In the U.S., about 2/3 of patients have no available treatment. And that unmet need was truly reinforced through our interactions with patients and physicians earlier in the month, when we had the opportunity to attend the Thalassemia International Federation Pan American conference, which left us with a great deal of energy and excitement about the potential launch ahead.
Brian Goff
executiveRight, that sounds good. And Salveen, if we circle back to those figures briefly — Tsveta raised something that comes up often, which is how dependable those figures are, meaning the 4,000 patients. It matters quite a bit that in thalassemia these ICD-10 codes have existed for a very long while. So those figures carry a great deal of rigor. And I would simply note that this stands in contrast with PKD, where the codes, quite literally, were set up just before launch. So the dynamic there is really quite different. And perhaps I could just ask Cecilia to weigh in on what lies ahead — looking at it through a revenue lens, with a possible launch, how the fourth quarter might shape up.
Cecilia Jones
executiveYes, thank you, Brian. So considering the PDUFA target that's anticipated in September, plus the duration required from a PF until patients begin therapy, from a revenue standpoint during this year—2025—we do not anticipate thalassemia revenues being material.
Emily Bodnar
analystFor the first one, I suppose, could you possibly discuss what the pediatric opportunity looks like in thalassemia, and do you have any timing around a potential FDA filing there? And then, maybe, could you just confirm that nothing has changed regarding either access or, I guess, the tone of your conversations with the FDA in recent weeks, given some of the news happening there?
Brian Goff
executiveSure. Thanks, Emily. What about this — Tsveta can begin with pediatric from a commercial perspective, and then Sarah can reflect on the trials and the pathway ahead.
Tsveta Milanova
executiveSure. In the U.S., roughly 8,000 people have thalassemia. As mentioned, around 6,000 of them are down. That leaves 2,000 who are pediatric patients. Naturally, this is a genetic condition, so diagnosis happens at birth. Newborn screening is available. Because of that, diagnosis rates for this disease are high, and there's consistently a substantial unmet need, plus a chance for us to deliver value among pediatric patients. With that said, I'll turn things over to Sarah.
Sarah Gheuens
executiveOur strategy for developing this in kids is to first establish the benefit-risk picture in grown-ups, and that's something we've got now. So for the thalassemia indication, the approach mirrors what was done in pyruvate kinase deficiency — we broaden it out by conducting studies in pediatric patients. After those results come in, we'll go ahead and submit them to the regulators for their assessment.
Brian Goff
executiveEmily, regarding the latter portion of what you asked—that concerned our dealings with the FDA. Naturally, we won't get into details, but Sarah, is there anything you'd like to say regarding how we've been engaging?
Sarah Gheuens
executiveAbsolutely — we've consistently taken pride in working together and building relationships with every regulator we deal with. So yes, I'm aware of the disruption that's been in the news, but when it comes to our team's interactions with the FDA, we haven't seen anything like major disruptions, and it's still a collaborative engagement.
Alec Stranahan
analystThis is Matthew, filling in for Alec. Let's begin with our first one. I realize the launch is initially concentrated on patients who visit more often. For those beyond that initial group, I'm wondering what the main educational messages would be to encourage adoption, and does that look different between the U.S. and outside the U.S.? Then perhaps a second one regarding the early-stage pipeline. I'd like to know whether anything has shifted in your PKU development strategy following the approval of PTC's second.
Brian Goff
executiveAll right. Thank you, Matthew. Tsveta, why don't you take the question about what segmentation looks like beyond those initial higher frequency clinical touch points?
Tsveta Milanova
executiveSure. So like we mentioned, the patients we focus on first are those who are transfusion-dependent or non-transfusion-dependent and need extra care because of the symptoms their disease causes. Once we look past that group, we'll keep growing into the non-transfusion-dependent patients who may have symptoms but may not be prepared to start treatment right away. We also need to keep in mind that as patients get older, the burden of their disease grows, so they may in fact be developing complications from the disease too. The main educational points will stay the same; we know the unmet need in thalassemia is well characterized. But this is a field that keeps evolving, and more data on unmet need, particularly among non-transfusion-dependent patients, is coming out. So a great deal of our educational work is really about spreading that extra information and staying engaged with both patients and physicians. We're also emphasizing how important it is to keep monitoring these patients continuously, given the long-term complications of the disease and its pathophysiology, which matters to us. So once we're set to expand, we'll have patients and the physician community more engaged on that front. They'll be consistent in the U.S.; and outside the U.S., naturally. Our priorities and segmentation around the world will stay fairly consistent; still, outside the U.S. we'll have to handle different market access dynamics and patient access, and we'll tackle that with our partners suitably, country by country.
Brian Goff
executiveTo underscore what Tsveta said regarding outside America, our geographic focus is very well defined. The U.S. stands as our top priority, which is the reason Tsveta and her group built things around going straight to market ourselves, and we take real pride in the alliances already put in place and refreshed — in fact, this morning — with Avanzanite Biosciences for Europe, plus NewBridge covering the GCC. As I mentioned, that method uses capital very efficiently, yet it likewise depends on know-how specific to those regions. Then, turning to the second question on PKU, perhaps Sarah can take that one.
Sarah Gheuens
executiveRight. So no modifications were made by us in response to that recent approval. That approval has us quite enthusiastic, since it lets us keep track of what takes place and, naturally, gain knowledge from those patients as they move forward. Yet at the core, the same tenets guiding our program stay unchanged, given that what we have is essentially a phenylalanine hydroxylase stabilizer drug — an entirely novel mechanism of action, an oral therapy that could genuinely bring another option to patients who continue to face a severe need. Even with this recent approval, a severe — severe need for additional choices will persist, because these patients may end up not responding to the treatments, or they could — take Palynziq, for instance, where anaphylaxis or similar events may occur. So a large, large gap will remain to be filled. That is even visible in the label the new drug currently carries, since the stopping criteria applied when no treatment response is seen mean there will in effect be individuals who do not respond to this therapy and will require other choices.
Brian Goff
executivePKU fits perfectly into the area where Agios thrives, since we take great pride in creating new approaches for conditions where patients still lack adequate options. In the same way we approach thalassemia, sickle cell, PKD, and every other condition we're going after, any kind of innovation matters. We enjoyed seeing the update you mentioned, and we're genuinely enthusiastic about how our own PAH hydroxylase stabilizer, 181, is coming along. So, many thanks.
Andrew Berens
analystCongratulations on the progress everyone's made. I'd like to follow up on what Marc asked earlier. Since you flagged the liver injury risks at ASH 2024, has the sickle cell trial protocol been modified in any way? I'm curious whether the consent forms or the monitoring requirements are different now; and then I have a question about tebapivat. We saw that the tebapivat study is using doses that are noticeably lower than the MDS Phase IIb trials that are running. Could you talk about the dosing protocol for this trial and why you're going lower in the sickle cell trial? Do you have data at those doses in MDS and sickle cell that you could share with us? Hello?
Sarah Gheuens
executiveYes. Okay. So, regarding the protocol for sickle cell disease, we said previously that once this risk came to light in the thalassemia program, we had brought all of our protocols into alignment so that there is monthly monitoring across the first 6 months, including our open-label extension trial; so, for the protocol in sickle cell disease, we aligned the open-label extension study so it matches what takes place in the first part of the randomized controlled trial, since placebo patients clearly are dosed for the first time when they enter the open-label extension study. So, we ensured they receive the same kind of monitoring; and so that's essentially captured in the protocols, and we also updated those informed consents, of course. And as for your next question about how dosing differs between the sickle cell disease Phase II and the MDS Phase IIb. You're correct, we are looking at lower doses in the sickle cell disease Phase II, and the reason is that in sickle cell disease patients, their metabolism is consistent with the healthy volunteer metabolism seen in the Phase I. As a reminder, sickle cell disease patients were included in that trial too. So, we have that. But then in the MDS trial, in the IIa, we saw that MDS patients metabolize the drug more quickly. So, we adjusted the doses accordingly. And so that's what you'll see we are exploring — that's the reason we are exploring different doses for sickle cell disease and MDS.
Tessa Romero
analystSo, circling back to a couple of the questions asked earlier on this call, is it still fair to think that the possible danger of hepatocellular injury will remain in the warnings and precautions section of the label, the way it currently stands today? And on a related note, at what point do you anticipate sharing your open-label extension data that you've gathered in this population, which could be relevant to physicians and institutions as they start prescribing in thalassemia?
Brian Goff
executiveSure. Thanks. Sarah can handle both of those. On the open-label extension, I'll just mention that we're interested in the data too, obviously, but we're going to proceed in sequence; but go ahead.
Sarah Gheuens
executiveSure. Actually, maybe I should start with that topic first — about the open-label extension, you're going to see us put out data from the open-label extensions, which is what we always do, just the same as we've already done in PKD. Obviously, right now, our main attention is on the reviews that are underway, and we'd rather have those teams spend their time on that than try to publish anything extra about the extension data. Still, that's absolutely going to happen. It's clearly something we're also interested in. And you're right that interest from everyone isn't going away. So there's more to come on that front; and then as for your question on HCI and where it appears in the label, Brian raised that point a bit earlier. Obviously, we remain in ongoing conversations with the agency as matters move forward, since the benefit-risk assessment is still being conducted alongside them. As I understand it right now, whatever appears — whatever has been captured in the PKD label up to this point matches what we've seen in our own program, which is accurate; that same wording, for a different condition and at a greater dose, can be found within the warnings and precautions portion of the PKD label. At some point, once the thalassemia label is finalized, that wording will need to be revised. Regarding its ultimate placement or the specific revisions involved, we refrain from commenting on reviews that are still in progress with the agency. However, the action date we're working toward is September 7 — that's when the review ought to wrap up. After that, once everyone has the finalized label in hand, we can go into more detail about it.
Greg Harrison
analystTheresa here, filling in for Greg. Before the thalassemia launch — which could be coming — I was hoping you might give us more detail about which prescribers you'll target first, and how you intend to handle differences in treatment approach between academic centers and community hematologists.
Brian Goff
executiveYes, thanks, Theresa. Sarah can go over some of what we discussed before — in the U.S., those 4,000 patients who make up our addressable target — and then say a bit more about community versus academic.
Sarah Gheuens
executiveYes, so Theresa, like I said, here in the U.S. we get a real advantage because thalassemia patients have a diagnosis and solid ICD-10 codes behind them. That gives us a great deal of visibility into where those patients are receiving treatment and care right now. Beyond that, the team has stayed extremely focused on very thorough launch preparations, which gave us the chance to reach out to the prescribing community, profile the accounts, and genuinely rank them in the right order according to which patients they hold and how willing they might be to keep managing those patients. Naturally, most of the transfusion-dependent patients sit inside academic centers, and that's where you'll notice somewhat greater penetration when it comes to the transfusion-dependent setting. That said, unmet need runs very high among non-transfusion-dependent patients, and that need is quite well characterized and understood; even if a number of these patients get managed out in the community, we've managed to engage those prescribers, figure out where these patients receive care, deliver disease education, and rank those accounts so we can pull them through launch too, right at the start of the launch.
Brian Goff
executiveAlright. Michelle, I appreciate it, and many thanks to all of you for joining us on today's call. As everybody is aware, we've reached the midpoint of what has been another active year. This is a particularly thrilling period for Agios, and we firmly hold the view that we're positioned to bring forward groundbreaking new treatments for patients while generating substantial value for shareholders over the long term. So, once more, thank you, and we can't wait to talk with you again before long.
Operator
operatorThat wraps up the conference call for today. Thanks for joining in, and you're free to disconnect at this point. Have a wonderful day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.